The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of ImmunityBio Inc (NASDAQ: IBRX) was $2.64 for the day, down -2.22% from the previous closing price of $2.7. In other words, the price has decreased by -$2.22 from its previous closing price. On the day, 5.14 million shares were traded. IBRX stock price reached its highest trading level at $2.785 during the session, while it also had its lowest trading level at $2.62.
Ratios:
Our analysis of IBRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.05 and its Current Ratio is at 2.22.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2383075328 and an Enterprise Value of 3092036864. For the stock, the TTM Price-to-Sale (P/S) ratio is 74.64. Its current Enterprise Value per Revenue stands at 99.034 whereas that against EBITDA is -10.425.
Stock Price History:
The Beta on a monthly basis for IBRX is -0.01, which has changed by -0.57281554 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $7.48, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is -1.43%, while the 200-Day Moving Average is calculated to be -20.63%.
Shares Statistics:
IBRX traded an average of 9.34M shares per day over the past three months and 7200680 shares per day over the past ten days. A total of 853.39M shares are outstanding, with a floating share count of 91.82M. Insiders hold about 89.60% of the company’s shares, while institutions hold 9.08% stake in the company. Shares short for IBRX as of 1749772800 were 72356035 with a Short Ratio of 7.75, compared to 1747267200 on 73740245. Therefore, it implies a Short% of Shares Outstanding of 72356035 and a Short% of Float of 31.680000000000003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of ImmunityBio Inc (IBRX) is currently drawing attention from 2 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.44 and -$0.55 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.27, with 2.0 analysts recommending between -$0.26 and -$0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $24.5M to a low estimate of $20M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $1.05MFor the next quarter, 4 analysts are estimating revenue of $27.85M. There is a high estimate of $35.39M for the next quarter, whereas the lowest estimate is $22M.
A total of 4 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $124M, while the lowest revenue estimate was $83.52M, resulting in an average revenue estimate of $99.35M. In the same quarter a year ago, actual revenue was $14.74MBased on 4 analysts’ estimates, the company’s revenue will be $228.32M in the next fiscal year. The high estimate is $273.6M and the low estimate is $177.59M.
